文献速递产科母胎医学

孕期沙眼衣原体加速伴侣治疗项目的实际效果

Effectiveness of Chlamydia trachomatis expedited partner therapy in pregnancy.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-22

在高衣原体流行县公立医院开展孕期加速伴侣治疗(EPT)项目,为感染孕妇提供阿奇霉素单剂包治疗伴侣。前瞻性观察471例与既往419例传统伴侣转诊者比较,重复检测再感染率无统计学差异(13% vs 15%)。母婴次要结局无差异,子宫内膜炎有改善趋势。

要点

  • 孕期EPT项目实施后衣原体再感染率未显著低于传统伴侣转诊(13% vs 15%)。
  • 符合方案分析中两组的再感染率仍无统计学差异(P=.47)。
  • 子宫内膜炎在EPT组有改善趋势(OR 0.13,95%CI 0.02-1.02)。

核心结论

  • 孕期实施加速伴侣治疗项目未影响分娩前沙眼衣原体再感染率。
  • 城市高风险人群衣原体治疗成功受多因素影响,未来需探索患者教育和安全性行为等综合措施。

研究设计与样本

  • 前瞻性观察研究,2019年8月21日起在衣原体高流行县公立医院实施孕期EPT项目。
  • EPT组为同年分娩的471例孕妇,历史对照组为前一年分娩的419例接受传统伴侣转诊检测治疗的孕妇。
  • 排除合并淋病、HIV、梅毒或当前亲密伴侣暴力的孕妇。

主要发现

  • 2年分娩人群中衣原体感染率为3.6%。
  • EPT组再感染60/471(13%),对照组61/419(15%),OR 0.86(95%CI 0.58-1.26)。
  • 符合方案分析中,对照组72例(17%)和EPT组389例(83%)接受EPT,再感染率无统计学差异(P=.47)。
  • 母婴次要结局无差异,子宫内膜炎在EPT组有改善趋势(OR 0.13,95%CI 0.02-1.02)。

关键数值与推荐

  • 主要结局为治疗后4-6周重复检测或36周产前筛查时的衣原体再感染或无治愈率。
  • 次要结局包括胎膜早破、绒毛膜羊膜炎、子宫内膜炎、新生儿重症监护入院、新生儿败血症、肺炎和结膜炎。

临床怎么用

  • 孕期衣原体感染可考虑EPT作为伴侣管理策略之一,但需认识到其单独使用可能不足以降低再感染率。
  • 应结合患者教育和安全性行为指导等综合措施来减少孕期衣原体再感染。

局限性

  • 研究为单中心前瞻性观察,非随机对照,可能存在混杂偏倚。
  • 历史对照可能受时间趋势和未测量因素影响。
  • 排除合并淋病、HIV、梅毒或亲密伴侣暴力的孕妇,结果外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Expedited partner therapy for Chlamydia trachomatis has had mixed efficacy in different populations, but limited data exist on the efficacy of the therapy in a pregnant population. OBJECTIVE: This study aimed to evaluate the real-world effectiveness of establishing a prenatal expedited partner therapy program in eradicating chlamydia before delivery and to examine the maternal and neonatal outcomes between women who received expedited partner therapy for chlamydia and women who received standard partner referral testing and treatment during pregnancy. STUDY DESIGN: An expedited partner therapy program was implemented on August 21, 2019, at a public hospital in a county with high chlamydia prevalence. Pregnant women were provided with single-dose packets of azithromycin to treat partners following a diagnosis of chlamydia infection. We prospectively observed pregnant women treated in the expedited partner therapy program who delivered at our institution in the same year and compared the outcomes with a historic cohort from the previous year that had traditional partner referral testing and treatment. We excluded women with concurrent gonorrhea, HIV, syphilis, or current intimate partner violence. The primary outcome was chlamydia reinfection or no-cure rates at repeat testing in 4 to 6 weeks following treatment or at the 36-week prenatal care screening. Secondary outcomes included obstetrical, maternal, and neonatal outcomes, including premature rupture of membranes, chorioamnionitis, endometritis, neonatal intensive care unit admission, neonatal sepsis, pneumonia, and conjunctivitis. RESULTS: The rate of chlamydia infection was 3.6% over a 2-year period in our delivered population. In the year following the implementation of the expedited partner therapy, compared with 419 women (mean±standard deviation, 23.4±5.5 years) who were diagnosed with chlamydia infection in the previous year, 471 women (mean±standard deviation age, 23.8±5.3 years) who delivered at our institution were diagnosed with chlamydia infection. There was no difference in race, parity, prenatal care attendance, or concomitant sexually transmitted infections. Compared with the pre-expedited partner therapy group, the rate of reinfection in the post-expedited partner therapy group was not statistically different (60/471 [13%] vs 61/419 [15%]; odds ratio, 0.86 [95% confidence interval 0.58-1.26]). In a per-protocol analysis, 72 women (17%) in the pre-expedited partner therapy group and 389 women (83%) in post-expedited partner therapy group received expedited partner therapy; reinfection was not statistically different between groups (P=.47). There was no difference in secondary outcomes, although a trend toward improved rates of endometritis was noted in the post-expedited partner therapy group (odds ratio, 0.13; 95% confidence interval, 0.02-1.02). CONCLUSION: The implementation of a prenatal expedited partner therapy program did not affect the rate of chlamydia reinfection before delivery. Treatment of chlamydia in an inner-city population has multiple factors that lead to successful treatment. Future efforts to reduce sexually transmitted infection and chlamydia reinfection rates in an at-risk population should include exploring patient education and safe sex practices beyond expedited partner therapy alone during pregnancy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Zofkie AC, Fomina YY, Roberts SW, et al. Effectiveness of Chlamydia trachomatis expedited partner therapy in pregnancy. Am J Obstet Gynecol. 2021. PMID: 33894150. doi:10.1016/j.ajog.2021.04.238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。